Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomized, double blind placebo-controlled study to assess the safety, tolerability, pharmacokinetics, and preliminary pharmacodynamics of single and multiple ascending doses of QBW251 in healthy subjects and multiple doses in cystic fibrosis patients

Next Previous
Trial Profile

A randomized, double blind placebo-controlled study to assess the safety, tolerability, pharmacokinetics, and preliminary pharmacodynamics of single and multiple ascending doses of QBW251 in healthy subjects and multiple doses in cystic fibrosis patients

Status: Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 06 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Icenticaftor (Primary)
  • Indications Cystic fibrosis
  • Focus Adverse reactions; First in man; Proof of concept; Therapeutic Use
  • Sponsors Novartis

Most Recent Events

  • 19 May 2021 Results of an analysis assessing the effect of the CFTR potentiator Icenticaftor (QBW251) on plasma Proteome in COPD patients with Chronic Bronchitis presented at the 117th International Conference of the American Thoracic Society
  • 27 Jul 2020 This trial is completed in UK (Global End Date: 20 Nov 2015), according to European Clinical Trials Database record.
  • 29 Feb 2016 Status changed from recruiting to discontinued as per ClinicalTrials.gov record.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top